Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.

Liu S, Wang K, Chen H, Wan Z, Dou L, Li S

Open source

DOI
10.1016/j.breast.2026.104889
Published
2026 Oct
Container
Breast (Edinburgh, Scotland)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2026.104889,
  title = {Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.},
  author = {Liu S and Wang K and Chen H and Wan Z and Dou L and Li S},
  year = {2026},
  journal = {Breast (Edinburgh, Scotland)},
  doi = {10.1016/j.breast.2026.104889},
  url = {https://doi.org/10.1016/j.breast.2026.104889}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.
AU  - Liu S
AU  - Wang K
AU  - Chen H
AU  - Wan Z
AU  - Dou L
AU  - Li S
PY  - 2026
JO  - Breast (Edinburgh, Scotland)
DO  - 10.1016/j.breast.2026.104889
UR  - https://doi.org/10.1016/j.breast.2026.104889
ER  - 

APA

S, L., K, W., H, C., Z, W., L, D., & S, L. (2026). Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.. Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2026.104889

Source records